447 related articles for article (PubMed ID: 24189892)
1. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
Dalton JT; Taylor RP; Mohler ML; Steiner MS
Curr Opin Support Palliat Care; 2013 Dec; 7(4):345-51. PubMed ID: 24189892
[TBL] [Abstract][Full Text] [Related]
2. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
[TBL] [Abstract][Full Text] [Related]
3. Enobosarm (GTx-024, S-22): a potential treatment for cachexia.
Srinath R; Dobs A
Future Oncol; 2014 Feb; 10(2):187-94. PubMed ID: 24490605
[TBL] [Abstract][Full Text] [Related]
4. Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials.
Fonseca GWPD; Dworatzek E; Ebner N; Von Haehling S
Expert Opin Investig Drugs; 2020 Aug; 29(8):881-891. PubMed ID: 32476495
[TBL] [Abstract][Full Text] [Related]
5. Enobosarm (GTx-024) Modulates Adult Skeletal Muscle Mass Independently of the Androgen Receptor in the Satellite Cell Lineage.
Dubois V; Simitsidellis I; Laurent MR; Jardi F; Saunders PT; Vanderschueren D; Claessens F
Endocrinology; 2015 Dec; 156(12):4522-33. PubMed ID: 26393303
[TBL] [Abstract][Full Text] [Related]
6. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery.
Segal S; Narayanan R; Dalton JT
Expert Opin Investig Drugs; 2006 Apr; 15(4):377-87. PubMed ID: 16548787
[TBL] [Abstract][Full Text] [Related]
8. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.
Solomon ZJ; Mirabal JR; Mazur DJ; Kohn TP; Lipshultz LI; Pastuszak AW
Sex Med Rev; 2019 Jan; 7(1):84-94. PubMed ID: 30503797
[TBL] [Abstract][Full Text] [Related]
9. Selective androgen receptor modulators as function promoting therapies.
Bhasin S; Jasuja R
Curr Opin Clin Nutr Metab Care; 2009 May; 12(3):232-40. PubMed ID: 19357508
[TBL] [Abstract][Full Text] [Related]
10. Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity.
Yarrow JF; McCoy SC; Borst SE
Steroids; 2010 Jun; 75(6):377-89. PubMed ID: 20138077
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of an imidazolopyrazole as novel selective androgen receptor modulator.
Zhang X; Allan GF; Tannenbaum P; Sbriscia T; Linton O; Lai MT; Haynes-Johnson D; Bhattacharjee S; Lundeen SG; Sui Z
J Steroid Biochem Mol Biol; 2013 Mar; 134():51-8. PubMed ID: 23098693
[TBL] [Abstract][Full Text] [Related]
12. Considerations, possible contraindications, and potential mechanisms for deleterious effect in recreational and athletic use of selective androgen receptor modulators (SARMs) in lieu of anabolic androgenic steroids: A narrative review.
Machek SB; Cardaci TD; Wilburn DT; Willoughby DS
Steroids; 2020 Dec; 164():108753. PubMed ID: 33148520
[TBL] [Abstract][Full Text] [Related]
13. [A potential of selective androgen receptor modulator(SARM)for the therapy of osteoporosis].
Yanase T
Clin Calcium; 2016 Jul; 26(7):1023-30. PubMed ID: 27346314
[TBL] [Abstract][Full Text] [Related]
14. Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids.
Choi SM; Lee BM
Expert Opin Drug Saf; 2015; 14(11):1773-85. PubMed ID: 26401842
[TBL] [Abstract][Full Text] [Related]
15. Detection of SARMs in doping control analysis.
Thevis M; Schänzer W
Mol Cell Endocrinol; 2018 Mar; 464():34-45. PubMed ID: 28137616
[TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia.
Zilbermint MF; Dobs AS
Future Oncol; 2009 Oct; 5(8):1211-20. PubMed ID: 19852734
[TBL] [Abstract][Full Text] [Related]
17. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.
Dobs AS; Boccia RV; Croot CC; Gabrail NY; Dalton JT; Hancock ML; Johnston MA; Steiner MS
Lancet Oncol; 2013 Apr; 14(4):335-45. PubMed ID: 23499390
[TBL] [Abstract][Full Text] [Related]
18. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile.
Rosen J; Negro-Vilar A
J Musculoskelet Neuronal Interact; 2002 Mar; 2(3):222-4. PubMed ID: 15758439
[TBL] [Abstract][Full Text] [Related]
19. An update on promising agents for the treatment of cancer cachexia.
Madeddu C; Mantovani G
Curr Opin Support Palliat Care; 2009 Dec; 3(4):258-62. PubMed ID: 19667995
[TBL] [Abstract][Full Text] [Related]
20. Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology.
Anker MS; von Haehling S; Springer J; Banach M; Anker SD
Int J Cardiol; 2013 Jan; 162(2):73-6. PubMed ID: 23174169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
